Strategic rollout across major e-commerce platforms in the U.S. and UK reinforces APR's expanding global beauty device footprint.Sequential launches planned across TikTok Shop and...
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
HONG KONG, June 11, 2026 /PRNewswire/ -- At Tencent Cloud Day Hong Kong, Tencent Cloud, the cloud business of Tencent, announced a strategic collaboration with...
From Pearl Studio, the Studio Behind Kung Fu Panda 3, the Mythological Comedy Marks the Next Major Chinese Animated Release as Chinese Animation Continues...
HEFEI, China, June 10, 2026 /PRNewswire/ -- Sungrow recently announced that its SG510HX utility string inverter (SG465HX for the Middle East region, offering equivalent...
Appointment expands consumer choice and convenience to American Standard products and solutions to Australians nationwide for both retail and commercial marketsMELBOURNE, Australia, June 11, 2026...
New collaboration brings Visa's global payment network to one of the largest AI platforms and aims to support seamless, secure transactions and broader AI-powered...
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
This year's winners showcase the richness and range of Ontario's English and French literary talent TORONTO, June 10, 2026 /CNW/ - Ontario Creates, a...
SYDNEY, June 11, 2026 /PRNewswire/ -- Insta360 announced Luna Ultra, its flagship gimbal camera co-engineered with Leica, built to combine professional imaging, 3-axis stabilization, and...
Key Highlights:SeAH A&D has received Boeing's Supplier Production Partner Award in recognition of its outstanding performance and operational excellence within Boeing's commercial aircraft supply...